Trial · NCT05965427
Outcomes18
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 18 of 18
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Severe Mpox Lesions | From date of disease onset (first symptom) until date of peak number of lesions and sites recorded (up to 3 months) | Skin lesion severity could not be analysed for all participants as the number of lesions were not available due to the retrospective data collection nature of this study. | participants | NUMBER |
| PRIMARY | Clinical Complications Associated With Mpox | From date of disease onset (first symptom) until date of clinical resolution e.g. lesion resolution, hospital discharge or death (up to 3 months) | Clinical complication data was not available for available for all participants due to the retrospective data collection nature of this study. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Number of Hospitalisation Events | From date of disease onset (first symptom) until date of clinical resolution e.g. lesion resolution, hospital discharge or death (up to 3 months) | Events | NUMBER | |
| PRIMARY | Death | From date of disease onset (first symptom) until date of death related to Mpox (up to 3 months) | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Differences in Mpox Lesion Severity (the Clinical Manifestation) in PLWHIV and PrEP Users | From date of disease onset (first symptom) until date of clinical resolution e.g. lesion resolution, hospital discharge or death (up to 3 months) | participants | NUMBER | |
| PRIMARY | Differences in the Clinical Manifestation of Mpox in PLWHIV and PrEP Users by Site of Lesions | From date of disease onset (first symptom) until date of clinical resolution e.g. lesion resolution, hospital discharge or death (up to 3 months) | Site of lesion data was not available for all participants due to the retrospective data collection in this study. | participants | NUMBER |
| PRIMARY | Differences in the Clinical Manifestation of Mpox in PLWHIV and PrEP Users by Severity Indicators | From date of disease onset (first symptom) until date of clinical resolution e.g. lesion resolution, hospital discharge or death (up to 3 months) | Severity indicators were not available for all participants due to the retrospective nature of this data collection study. | participants | NUMBER |
| PRIMARY | Differences in the NEWS2 Score ≥5 (Severity Indicator) in PLWHIV and PrEP Users With Mpox | From date of disease onset (first symptom) until date of clinical resolution e.g. lesion resolution, hospital discharge or death (up to 3 months) | NEWS2 score was not available for all participants due to the retrospective nature of this data collection study. | participants | NUMBER |
| PRIMARY | Differences in the Drug Treatments of Mpox in PLWHIV and PrEP Users | From date of disease onset (first symptom) until date of clinical resolution e.g. lesion resolution, hospital discharge or death (up to 3 months) | Drug treatment for mpox data was not available for all participants. Due to the retrospective nature of this data collection study, only available data was collected for analysis. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Differences in the Drug Treatments for Complications of Mpox in PLWHIV and PrEP Users | From date of disease onset (first symptom) until date of clinical resolution e.g. lesion resolution, hospital discharge or death (up to 3 months) | Drug treatment for Mpox complications data was not available for all participants. Due to the retrospective nature of this data collection study, only available data was collected for analysis. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Differences in the First Symptom at Onset of Mpox in PLWHIV and PrEP Users | Mpox onset | First symptom at Mpox onset was not available/unknown for all participants due to the retrospective data collection in this study. | participants | NUMBER |
| PRIMARY | Mpox Transmission | Mpox onset | participants | NUMBER | |
| PRIMARY | Mpox Transmission Characteristics | Mpox onset | Days between symptom onset and positive PCR test data was not available for all participants due to the retrospective nature of this data collection study. | days | MEDIAN |
| PRIMARY | Risk Factors for Mpox Outcomes | From date of disease onset (first symptom) until date of clinical resolution e.g. lesion resolution, hospital discharge or death (up to 3 months) | Severe lesion endpoint data was not available for all participants due to the retrospective nature of this data collection study. No events occurred in some groups and were therefore not included in this analysis. | participants | NUMBER |
| PRIMARY | Risk Factors for Mpox Outcomes for PLWHIV | From date of disease onset (first symptom) until date of clinical resolution e.g. lesion resolution, hospital discharge or death(up to 3 months) | CD4 data was not available for all participants due to the retrospective nature of this data collection study. | cells/mm^3 | MEAN |
| SECONDARY | Prevalence of Mpox During the Study Period | 1st May 2022 to 1st December 2023 | All patient data was not available at 2 sites, Hospital Clinic Barcelona and EECE Warsaw, and are excluded from this analysis. | percentage of mpox cases | NUMBER |
| SECONDARY | Length of Stay in Hospital | From date of hospital admission for Mpox until date of hospital discharge (up to 3 months) | days | MEDIAN | |
| SECONDARY | Time to Lesion Resolution (if Known) | From date of disease onset (first symptom) until date of lesion resolution (up to 3 months) | days | MEDIAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05965427/outcomes